ArticleLung India : official organ of Indian Chest Society2026
Optimizing adult pneumococcal vaccination in India: Evidence from serotype surveillance.
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPneumococcal disease, caused by Streptococcus pneumoniae , is a major public health burden with high morbidity and mortality across all age groups in India. Limited adult pneumococcal vaccination policies, evolving serotype patterns, and delayed herd protection from paediatric immunization continue to challenge effective prevention of pneumococcal disease in adults.
methodsThis retrospective laboratory surveillance study includes Streptococcus pneumoniae isolates from adults (>18 years) collected between January 2018 and May 2025 at Christian Medical College, Vellore and were serotyped using the Quellung and co-agglutination method. Percentage of serotype coverage for PCV20, PCV21, and PPSV23 was analysed.
resultsAmong 1,065 adult pneumococcal isolates, PCV20 covers 66.5% of invasive pneumococcal disease (IPD) serotypes, including emerging serotypes such as 15B and 11A, while PCV21 aligns poorly with the local epidemiology, covering only 46.5% of adult IPD serotypes. PPSV23 offers limited additional relevant serotype coverage beyond PCV20 and is limited by lower immunogenicity and hyporesponsiveness to multiple doses. DISCUSSION: Our findings highlight significant gaps between the circulating serotypes in adults in India and those covered by current vaccines. PCV20 shows promise for broader adult protection; however, further multi-centre studies, cost-effectiveness analyses, and enhanced surveillance are needed to inform policy and optimize immunization strategies in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.